Trastuzumab
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Carcinoma of Breast
Conditions
HER2-positive Carcinoma of Breast
Trial Timeline
Jun 1, 2014 → Oct 1, 2018
NCT ID
NCT02162667About Trastuzumab
Trastuzumab is a phase 3 stage product being developed by Celltrion for HER2-positive Carcinoma of Breast. The current trial status is completed. This product is registered under clinical trial identifier NCT02162667. Target conditions include HER2-positive Carcinoma of Breast.
What happened to similar drugs?
0 of 14 similar drugs in HER2-positive Carcinoma of Breast were approved
Approved (0) Terminated (0) Active (14)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02665637 | Phase 1 | Completed |
| NCT02162667 | Phase 3 | Completed |
Competing Products
20 competing products in HER2-positive Carcinoma of Breast